DSM Pharmaceutical Products has entered a license agreement with c-LEcta GmbH for its alcohol dehydrogenases screening technology for enzyme screening programs and development of sustainable manufacturing routes for pharmaceutical active ingredients and intermediates. The technology platform has been used by c-LEcta for the identification and optimization of biocatalysts, resulting in a collection of several hundred enzymes and qualified enzyme mutants. DSM will also provide commercializatio...